Your browser doesn't support javascript.
loading
PAR2 Modulators Derived from GB88.
Yau, Mei-Kwan; Liu, Ligong; Suen, Jacky Y; Lim, Junxian; Lohman, Rink-Jan; Jiang, Yuhong; Cotterell, Adam J; Barry, Grant D; Mak, Jeffrey Y W; Vesey, David A; Reid, Robert C; Fairlie, David P.
Afiliação
  • Yau MK; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Liu L; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Suen JY; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Lim J; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Lohman RJ; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Jiang Y; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Cotterell AJ; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Barry GD; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Mak JY; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Vesey DA; Centre for Kidney Research, Department of Medicine, The University of Queensland, Princess Alexandra Hospital , Brisbane, Queensland 4102, Australia.
  • Reid RC; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
  • Fairlie DP; Division of Chemistry and Structural Biology, Centre for Inflammation and Disease Research and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland , Brisbane, Queensland 4072, Australia.
ACS Med Chem Lett ; 7(12): 1179-1184, 2016 Dec 08.
Article em En | MEDLINE | ID: mdl-27994760
ABSTRACT
PAR2 antagonists have potential for treating inflammatory, respiratory, gastrointestinal, neurological, and metabolic disorders, but few antagonists are known. Derivatives of GB88 (3) suggest that all four of its components bind at distinct PAR2 sites with the isoxazole, cyclohexylalanine, and isoleucine determining affinity and selectivity, while the C-terminal substituent determines agonist/antagonist function. Here we report structurally similar PAR2 ligands with opposing functions (agonist vs antagonist) upon binding to PAR2. A biased ligand AY117 (65) was found to antagonize calcium release induced by PAR2 agonists trypsin and hexapeptide 2f-LIGRLO-NH2 (IC50 2.2 and 0.7 µM, HT29 cells), but it was a selective PAR2 agonist in inhibiting cAMP stimulation and activating ERK1/2 phosphorylation. It showed anti-inflammatory properties both in vitro and in vivo.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália